Investigators evaluated a large sample of commercially insured patients with prostate cancer to assess use of tissue-based gene expression testing.
Investigators used next-generation sequencing to characterize the genomic profile of squamous cell carcinoma (SCC) in 26 Colombian patients with lung SCC.
Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
Researchers have found a concerning level of distress in oncologists as a result of the COVID-19 pandemic that needs to be addressed so that they can better treat their patients and safeguard their own mental health.
Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone.
Investigators assessed sodium bicarbonate’s viability as a pharmacologic strategy in mouse models and humans with acute myeloid leukemia.
Efficacy data from expanded access programs were reported at ASH 2020, but whether these data will inform regulatory decisions remains to be seen.
“‘Trended strongly’ is code for ‘we failed to meet statistical significance,’” remarked one expert, when she was asked to scrutinize the conclusions of a recent post hoc analysis.
The pitfall of self-reported stress levels is that the baseline stress for some people is so high, a cancer diagnosis doesn’t even register.
Despite mixed evidence for the general population, cumulative research reveals dramatic improvement with convalescent plasma for blood cancer patients, especially when given early.
PD-1/PD-L1 inhibitors offer an improvement over standard of care in SCLC, but there is still a long way to go.
Investigators addressed challenges associated with the biology, diagnosis, and current state of treatment for patients with NPM1-mutated AML.
Investigators calculated patient community risk scores and center community risk scores to study the impact of community factors on patient outcomes following hematopoietic stem cell transplant.
Risk-stratification technology is evolving in chronic lymphocytic leukemia and can be used to guide treatment decisions and direct patients to clinical trials.
Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.